91 related articles for article (PubMed ID: 38690281)
21. Single-cell RNA sequencing reveals distinct T cell populations in immune-related adverse events of checkpoint inhibitors.
Bukhari S; Henick BS; Winchester RJ; Lerrer S; Adam K; Gartshteyn Y; Maniar R; Lin Z; Khodadadi-Jamayran A; Tsirigos A; Salvatore MM; Lagos GG; Reiner SL; Dallos MC; Mathew M; Rizvi NA; Mor A
Cell Rep Med; 2023 Jan; 4(1):100868. PubMed ID: 36513074
[TBL] [Abstract][Full Text] [Related]
22. Lower baseline autoantibody levels are associated with immune-related adverse events from immune checkpoint inhibition.
Ghosh N; Postow M; Zhu C; Jannat-Khah D; Li QZ; Vitone G; Chan KK; Bass AR
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35091456
[TBL] [Abstract][Full Text] [Related]
23. Association between immune-related adverse event timing and treatment outcomes.
Hsiehchen D; Naqash AR; Espinoza M; Von Itzstein MS; Cortellini A; Ricciuti B; Owen DH; Laharwal M; Toi Y; Burke M; Xie Y; Gerber DE
Oncoimmunology; 2022; 11(1):2017162. PubMed ID: 35003896
[TBL] [Abstract][Full Text] [Related]
24. Real-world data analyses unveiled the immune-related adverse effects of immune checkpoint inhibitors across cancer types.
Wang F; Yang S; Palmer N; Fox K; Kohane IS; Liao KP; Yu KH; Kou SC
NPJ Precis Oncol; 2021 Sep; 5(1):82. PubMed ID: 34508179
[TBL] [Abstract][Full Text] [Related]
25. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events.
Brahmer JR; Abu-Sbeih H; Ascierto PA; Brufsky J; Cappelli LC; Cortazar FB; Gerber DE; Hamad L; Hansen E; Johnson DB; Lacouture ME; Masters GA; Naidoo J; Nanni M; Perales MA; Puzanov I; Santomasso BD; Shanbhag SP; Sharma R; Skondra D; Sosman JA; Turner M; Ernstoff MS
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34172516
[TBL] [Abstract][Full Text] [Related]
26. Association between body mass index, dosing strategy, and efficacy of immune checkpoint inhibitors.
Ahmed M; von Itzstein MS; Sheffield T; Khan S; Fattah F; Park JY; Popat V; Saltarski JM; Gloria-McCutchen Y; Hsiehchen D; Ostmeyer J; Khan SA; Sultana N; Xie Y; Li QZ; Wakeland EK; Gerber DE
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34127546
[TBL] [Abstract][Full Text] [Related]
27. Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy.
Ghisoni E; Wicky A; Bouchaab H; Imbimbo M; Delyon J; Gautron Moura B; Gérard CL; Latifyan S; Özdemir BC; Caikovski M; Pradervand S; Tavazzi E; Gatta R; Marandino L; Valabrega G; Aglietta M; Obeid M; Homicsko K; Mederos Alfonso NN; Zimmermann S; Coukos G; Peters S; Cuendet MA; Di Maio M; Michielin O
Eur J Cancer; 2021 May; 149():153-164. PubMed ID: 33865201
[TBL] [Abstract][Full Text] [Related]
28. Immunotherapy Use in Patients With Lung Cancer and Comorbidities.
von Itzstein MS; Gonugunta AS; Mayo HG; Minna JD; Gerber DE
Cancer J; 2020; 26(6):525-536. PubMed ID: 33298724
[TBL] [Abstract][Full Text] [Related]
29. Immune-related adverse events of checkpoint inhibitors.
Ramos-Casals M; Brahmer JR; Callahan MK; Flores-Chávez A; Keegan N; Khamashta MA; Lambotte O; Mariette X; Prat A; Suárez-Almazor ME
Nat Rev Dis Primers; 2020 May; 6(1):38. PubMed ID: 32382051
[TBL] [Abstract][Full Text] [Related]
30. Investigational Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Event Prediction and Diagnosis.
von Itzstein MS; Khan S; Gerber DE
Clin Chem; 2020 Jun; 66(6):779-793. PubMed ID: 32363387
[TBL] [Abstract][Full Text] [Related]
31. Lack of Association Between Radiographic Tumor Burden and Efficacy of Immune Checkpoint Inhibitors in Advanced Lung Cancer.
Popat V; Lu R; Ahmed M; Park JY; Xie Y; Gerber DE
Oncologist; 2020 Jun; 25(6):515-522. PubMed ID: 32233048
[TBL] [Abstract][Full Text] [Related]
32. Association of Steroids use with Survival in Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
Petrelli F; Signorelli D; Ghidini M; Ghidini A; Pizzutilo EG; Ruggieri L; Cabiddu M; Borgonovo K; Dognini G; Brighenti M; De Toma A; Rijavec E; Garassino MC; Grossi F; Tomasello G
Cancers (Basel); 2020 Feb; 12(3):. PubMed ID: 32120803
[TBL] [Abstract][Full Text] [Related]
33. Relation of cetuximab-induced skin toxicity and early tumor shrinkage in metastatic colorectal cancer patients: results of the randomized phase 3 trial FIRE-3 (AIO KRK0306).
Holch JW; Held S; Stintzing S; Fischer von Weikersthal L; Decker T; Kiani A; Kaiser F; Heintges T; Kahl C; Kullmann F; Scheithauer W; Moehler M; von Einem JC; Michl M; Heinemann V
Ann Oncol; 2020 Jan; 31(1):72-78. PubMed ID: 31912799
[TBL] [Abstract][Full Text] [Related]
34. Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors.
Das S; Johnson DB
J Immunother Cancer; 2019 Nov; 7(1):306. PubMed ID: 31730012
[TBL] [Abstract][Full Text] [Related]
35. Variation in the Assessment of Immune-Related Adverse Event Occurrence, Grade, and Timing in Patients Receiving Immune Checkpoint Inhibitors.
Hsiehchen D; Watters MK; Lu R; Xie Y; Gerber DE
JAMA Netw Open; 2019 Sep; 2(9):e1911519. PubMed ID: 31532516
[TBL] [Abstract][Full Text] [Related]
36. Association of Prior Antibiotic Treatment With Survival and Response to Immune Checkpoint Inhibitor Therapy in Patients With Cancer.
Pinato DJ; Howlett S; Ottaviani D; Urus H; Patel A; Mineo T; Brock C; Power D; Hatcher O; Falconer A; Ingle M; Brown A; Gujral D; Partridge S; Sarwar N; Gonzalez M; Bendle M; Lewanski C; Newsom-Davis T; Allara E; Bower M
JAMA Oncol; 2019 Dec; 5(12):1774-1778. PubMed ID: 31513236
[TBL] [Abstract][Full Text] [Related]
37. Analysis of the Association Between Adverse Events and Outcome in Patients Receiving a Programmed Death Protein 1 or Programmed Death Ligand 1 Antibody.
Maher VE; Fernandes LL; Weinstock C; Tang S; Agarwal S; Brave M; Ning YM; Singh H; Suzman D; Xu J; Goldberg KB; Sridhara R; Ibrahim A; Theoret M; Beaver JA; Pazdur R
J Clin Oncol; 2019 Oct; 37(30):2730-2737. PubMed ID: 31116675
[TBL] [Abstract][Full Text] [Related]
38. Immune-related adverse events predict the therapeutic efficacy of anti-PD-1 antibodies in cancer patients.
Rogado J; Sánchez-Torres JM; Romero-Laorden N; Ballesteros AI; Pacheco-Barcia V; Ramos-Leví A; Arranz R; Lorenzo A; Gullón P; Donnay O; Adrados M; Costas P; Aspa J; Alfranca A; Mondéjar R; Colomer R
Eur J Cancer; 2019 Mar; 109():21-27. PubMed ID: 30682533
[TBL] [Abstract][Full Text] [Related]
39. Novel patterns of response under immunotherapy.
Borcoman E; Kanjanapan Y; Champiat S; Kato S; Servois V; Kurzrock R; Goel S; Bedard P; Le Tourneau C
Ann Oncol; 2019 Mar; 30(3):385-396. PubMed ID: 30657859
[TBL] [Abstract][Full Text] [Related]
40. Immune dysregulation in cancer patients developing immune-related adverse events.
Khan S; Khan SA; Luo X; Fattah FJ; Saltarski J; Gloria-McCutchen Y; Lu R; Xie Y; Li Q; Wakeland E; Gerber DE
Br J Cancer; 2019 Jan; 120(1):63-68. PubMed ID: 30377338
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
